Palisade Bio CEO Thomas Hallam resigns; CFO JD Finley appointed interim CEO

PALISADE BIO, INC.

CEO Thomas Hallam resigned effective Oct 11, 2022; separation agreement includes $530,000 paid over 12 months, COBRA, accelerated vesting.
JD Finley, current CFO, appointed interim CEO effective Oct 10; will continue as CFO.
Company will not present at American College of Surgeons Clinical Congress 2022 to focus on internal reorganization.
Dr. Hallam's resignation not due to any disagreement on operations, policies, or practices.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

J.D. Finley

Chief Executive Officer (principal executive officer), interim; continuing as Chief Financial Officer

PALI · PALISADE BIO, INC.

Effective: 2022-10-11
Filed: October 14, 2022, 7:59 PM ET

As of the Effective Date, J.D. Finley, the Company’s current Chief Financial Officer, was appointed by the Board to serve as the Company’s Chief Executive Officer (principal executive officer), on an interim basis.

Departed

Thomas Hallam

Chief Executive Officer and member of the Board of Directors

PALI · PALISADE BIO, INC.

Effective: 2022-10-11
Successor: J.D. Finley
Filed: October 14, 2022, 7:59 PM ET

Effective October 11, 2022 (the “Effective Date”), Thomas Hallam, Ph.D., the Chief Executive Officer and a member of the Board of Directors (the “Board”) of Palisade Bio, Inc. and its wholly owned subsidiary, Leading Biosciences, Inc. (collectively the “Company”) resigned as both Chief Executive Officer and as a member of the Board, of both entities, to pursue other opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

J.D. Finley was appointed as Chief Executive Officer (principal executive officer), interim; continuing as Chief Financial Officer at PALISADE BIO, INC..

Action: appointed
Role: Chief Executive Officer (principal executive officer), interim; continuing as Chief Financial Officer

Exact text from the filing

As of the Effective Date, J.D. Finley, the Company’s current Chief Financial Officer, was appointed by the Board to serve as the Company’s Chief Executive Officer (principal executive officer), on an interim basis.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas Hallam resigned as Chief Executive Officer and member of the Board of Directors at PALISADE BIO, INC..

Action: resigned
Role: Chief Executive Officer and member of the Board of Directors

Exact text from the filing

Effective October 11, 2022 (the “Effective Date”), Thomas Hallam, Ph.D., the Chief Executive Officer and a member of the Board of Directors (the “Board”) of Palisade Bio, Inc. and its wholly owned subsidiary, Leading Biosciences, Inc. (collectively the “Company”) resigned as both Chief Executive Officer and as a member of the Board, of both entities, to pursue other opportunities.

View on SEC.gov

PALISADE BIO, INC. filing history →

Source: SEC EDGAR

accession 0001493152-22-028453

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.